Anadys Pharmaceuticals, Inc. (ANDS) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-23.21M
Depreciation	157K
Share-based compensation expense	1.29M
Gain on valuation of common stock warrant liability issued in connection with equity financing	-1.42M
Gain from the sale of property and equipment	0
Amortization of discount on securities available-for-sale	357K
Prepaid expenses and other current assets	417K
Other assets	0
Accounts payable and accrued expenses	3.93M
Deferred rent	14K
Other current and long-term liabilities	-12K
Net cash used in operating activities	-18.48M
Purchases of securities available-for-sale	-10.54M
Proceeds from the maturity of securities available-for-sale	22.48M
Purchases of property and equipment	-30K
Proceeds from the sale of property and equipment	0
Net cash provided by investing activities	11.91M
Proceeds from equity financing, net of issuance costs	0
Proceeds from exercise of stock options and employee stock purchase plan	35K
Net cash provided by financing activities	35K
Net (decrease) increase in cash and cash equivalents	-6.54M
Cash and cash equivalents at beginning of period	7.62M
Cash and cash equivalents at end of period	1.08M
Unrealized gain (loss) on securities available-for-sale	13K

Entities mentioned with ANDS

View All Entities